Edison Investment Research - Speedy Hire PLC (SDY) Speedy Hire - Confident of sustainable UK earnings growth

Report

Edison Investment Research

Speedy Hire - Confident of sustainable UK earnings growth

Speedy Hire has signalled that it is fully through a transformation process and clearly focused on profitable growth. H1 revenue (ex-disposals) was almost 7% higher, at Â£183m, and management flagged that it expects to exceed previous adjusted PBT expectations for the full year by c 6-7%, which will form the base for future years. The positive results, benefiting from the recent operational restructuring, two recent bolt-on acquisitions and positive demand, point to sustained investor support.

30/11/2017 2 EN

Underlying

Speedy Hire PLC

Speedy Hire provides hire equipment and services to enable the delivery of customer projects. Co.'s reportable business segments comprise U.K. and Ireland Asset Services and International Asset Services. The U.K. and Ireland Asset Services delivers asset management, with tailored services and a continued commitment to relationship management. The International Asset Services delivers major overseas projects and facilities management contracts by providing a managed site support service.

See profile

GB0000163088 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Equity Development

Building a robust platform for growth - FY24 pre-close statement

Against a tough trading background in FY24, Speedy Hire has taken steps to build a platform for long term sustainable growth through the launch of its Velocity strategy. While progress has been more strategic than financial in the year – although we note positive underlying cash flow was achieved - new business wins, the acquisition of Green Power Hire and a transitioned B&Q model all suggest that profitability is likely to move ahead again from FY25 onwards. Speedy’s FY24 pre close statement echoed January’s trading update, pointing to successful new business wins with National customers but...

April 11, 2024 April 11, 2024 1 EN

SmartInsider

Speedy Hire: 3 directors

Three Directors at Speedy Hire bought 280,000 shares at between 25p and 25p. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

Free Trial

April 10, 2024 April 10, 2024 1 EN

Liberum

LIBERUM: UK Small & Mid Cap Dispatches

Ilika, ATOME Energy, Mitchells & Butlers, Ashtead Technology, On the Beach, Safestyle, SMID Market Highlights

May 18, 2023 May 18, 2023 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

22h / 4m 22h / 4m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN